期刊
TOXINS
卷 4, 期 6, 页码 430-454出版社
MDPI
DOI: 10.3390/toxins4060430
关键词
antibody; neutralization; protection; clearance; vaccine; therapeutics; isotype; animal model; in vivo; disease enhancement
资金
- Department of Defense [07164001, W81XWH08-01-0011]
- Northeast Biodefense Center [5U54AI05715807]
- [HL059842-3]
- [A1033774]
- [A1052733]
- [AI033142]
Antibody therapy remains the only effective treatment for toxin-mediated diseases. The development of hybridoma technology has allowed the isolation of monoclonal antibodies (mAbs) with high specificity and defined properties, and numerous mAbs have been purified and characterized for their protective efficacy against different toxins. This review summarizes the mAb studies for 6 toxins-Shiga toxin, pertussis toxin, anthrax toxin, ricin toxin, botulinum toxin, and Staphylococcal enterotoxin B (SEB)-and analyzes the prevalence of mAb functions and their isotypes. Here we show that most toxin-binding mAbs resulted from immunization are non-protective and that mAbs with potential therapeutic use are preferably characterized. Various common practices and caveats of protection studies are discussed, with the goal of providing insights for the design of future research on antibody-toxin interactions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据